Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Three concrete actions management should prioritize, ranked by potential impact:
1. Execute the Fleet Renewal with Precision: The market doesn't reward potential; it rewards execution. The new 60T AHTS vessels, scheduled for delivery in 2028, need to be delivered on time and on budget. These modern, more fuel-efficient vessels could significantly improve operational margins and contract rates, directly boosting future earnings.
2. Demonstrate Consistent Profitability: Investors need proof that the company can make money in any market, not just during oil price spikes. A key metric to watch is the Return on Equity (ROE). A sustained improvement in ROE, driven by higher vessel utilization and better cost management, would give investors a reason to buy, making the stock's low P/B ratio (0.4x) truly attractive.
3. Establish a Clear Capital Return Policy: A dividend is often a more credible signal of confidence than a buyback . The recent share capital reduction has cleared the path for future distributions . If Perdana can start paying a consistent, sustainable dividend, it would attract a whole new class of income-focused investors.
Six professionals, same facts, wildly different conclusions. This isn't a bug — it's the market's way of saying "we don't know."
Buffett and Munger don't read analyst reports for a reason: they're often backward-looking, constrained by career risk and can't replace primary research.
This is what you to do instead:
• Read the actual 4QFY26 financials and concall transcript
• Ask yourself: "Do I believe the ASP spike is durable? Can they pass through costs? Will China compete harder?"
• Your answer — not the analysts' — should drive your decision
Consensus analyst expectations project Top Glove’s Profit After Tax (PAT) to land in the range of RM95 million to RM100 million. If above will create momentary interest but if below will negate the interest for past few days. Let see how it unfolds. May the market forces be with everyone.
OS Capital Sdn Bhd is a licensed community credit provider and a wholly-owned subsidiary of OSK Holdings Berhad, a major Malaysian conglomerate.
🏢 About OS Capital
· Core Business: As a subsidiary of OSK Holdings, it specialises in providing non-bank financial solutions, such as financing and lending, to businesses and individuals.
· Key Personnel: The company recently posted a job opening for a "Manager, Debt Recovery & Remedial Management," indicating it operates with significant funds and credit resources.
🔗 Parent Company Context
· OSK Holdings: This is a diversified group with core businesses spanning Property, Financial Services, Industries, and Hospitality across Malaysia and Australia.
· Financial Strength: The Group manages total assets exceeding RM12 billion and shareholders' funds of RM8.8 billion, indicating strong financial backing for its subsidiaries.
In summary, the entry of OS Capital into FPI appears to be a strategic move by a larger Malaysian financial group. It is distinct from the other major shareholders like Formosa Prosonic Holdings or Denka Company (who are in the manufacturing sector).
INTCO Medical Technology Co., Ltd.
Global INTCO Global Health
Notice on Product Price Adjustment in INTCO Medical's Greater China Region
Dear Partners,
Greetings!
We sincerely thank you for your long-term trust in and support for INTCO Medical.
Affected by the sharp rise in global crude oil and bulk chemical prices, the overall cost of the industry has increased significantly. The core raw material for disposable nitrile gloves has soared and continues to show an upward trend. Our production costs have risen significantly, and the pressure on operating performance continues to increase. In the face of this situation, our company has made every effort to absorb cost pressures through internal controls. However, given the surge in core raw material costs, in order to ensure product quality, stabilize supply capacity, and maintain long-term stable cooperation, our company has decided after careful study:
Starting from September 9, 2026, based on differences in product specifications and gram weights, the prices of INTCO Medical's disposable nitrile gloves will increase by 15-40 RMB/carton. For specific matters, please consult with our business team, and we will answer your questions as soon as possible.
Once again, thank you for your understanding and strong support! INTCO Medical will, as always, adhere to quality and service, and work hand in hand with you to move forward steadily and develop together.
Wishing you prosperous business!
INTCO Medical Technology Co., Ltd.
September 8, 2026
The capital reduction is officially 100% complete.
The "Effective Date" has passed
· Date of completion: 14 August 2026 (the date it was lodged with the Registrar of Companies).
· The proposed reduction is now legally finalized and cannot be reversed.
The New Share Capital Structure
As stated in the announcement, the company's issued share capital is now reduced to RM282,286,743.36.
· Total ordinary shares: 2,227,909,141 (unchanged from before—your share count is the same).
· Total RCPS: 14,191,007 (down slightly from Q1 2026 as more RCPS converted).
· Important note: Since the share count didn't change, the share capital reduction was purely a book-keeping entry.
What happens to the Retained Earnings now?
· Before reduction (Q1 2026): Accumulated Losses of -RM205.6 million.
· Capital Reduction amount: The company wiped out RM600 million from the Share Capital account.
· New Retained Earnings: RM600m (wiped) – RM205.6m (previous losses) = approx. +RM394.4 million.
Perdana's balance sheet now officially has positive retained earnings for the first time in years.
What this means for you?
· Your shares: Exactly the same number. No dilution.
· No cash for you today: This is purely a balance sheet clean-up.
· The real payoff: Future dividends are now legally possible. Because they wiped out the negative retained earnings, Perdana can now pay dividends from future profits.
· Caveat: They can pay dividends, but they are still losing money operationally (Q1 2026 net loss of RM12.1M). Dividends won't happen until they return to consistent profitability.
Bottom line: The "financial engineering" is now fully done. The ball is now entirely on management to turn their operational cash flow into actual net profits with their new vessels.
The War of Attrition: Why Intco’s Price War Will Fail, and Why Hartalega Will Survive
In the current market, many investors are panicking over Hartalega's (HARTA) upcoming Q2 profit collapse. They see the ASP (Average Selling Price) dropping from US19, and they assume the glove recovery is dead.
But if you look beneath the surface—through the lens of forensic accounting and the Munger/Buffett mental model—a very different picture emerges.
This is not a story of industry failure. It is a story of a "War of Attrition" between two giants. And the math proves that Hartalega is the one that will walk away victorious.
The "Illogical" Strategy of Intco
The global glove industry is currently an Oligopoly trapped in a brutal price war. China’s Intco Medical is violating the fundamental Law of Supply. Even though ASPs have crashed to US$17–19 per 1,000 pieces—well below their manufacturing cost—they are cranking their factories to full capacity and flooding Europe and Asia with cheap gloves.
Why would they do this?
To bankrupt their competitors and seize market share.
But where is the money coming from?
Intco doesn't have the massive cash pile that Hartalega has. They are funding this suicidal price war through state-backed, ultra-low-interest loans from Chinese banks, and by burning through the capital they raised during the COVID boom. They are using borrowed money to sell gloves at a loss.
Why Intco Will Lose (The Munger Inversion)
If we invert the question, it becomes clear: How long can Intco bleed cash?
Intco is betting that Hartalega will blink first and cut production. They are wrong.
Hartalega’s Fortress:
· Cash Pile: RM 1.1 Billion (Zero net debt).
· Lowest Cost Structure: Plant 9’s automation has reduced headcount by 27.3% and slashed manufacturing costs to ~US$11.50 per 1,000 pieces.
· US Market Moat: With 100%+ US tariffs on Chinese gloves, Hartalega owns a protected market where they can still generate healthy margins.
In an Oligopoly price war, the winner is not the one who sells the cheapest—it is the one who can bleed the longest. Hartalega can bleed for 3–4 years. Intco cannot survive 2 years burning borrowed cash.
The Q2 "Crash": Why You Shouldn't Panic
Many investors are terrified of Hartalega's Q2 FY2027 results (due in November). The math shows profits will drop from RM70M back down to ~RM20M–RM25M.
This is not a sign of failure. This is a working capital cycle.
In Q1, Hartalega strategically hoarded RM465M worth of raw materials to secure supply before gas tariffs and NBR prices spiked further. In Q2, they will be forced to consume that expensive inventory while selling into a lower ASP environment. This creates a temporary "cost mismatch."
The silver lining: By Q3, the expensive inventory will be depleted, and Hartalega will return to buying cheaper raw materials. The margin recovery will be swift.
The Key Takeaway: Focus on Cash, Not Paper Profits
Over the last 4 quarters, Hartalega generated RM 792 Million in Operating Cash Flow against RM 160 Million in Net Profit.
An unethical CEO might massage depreciation numbers to inflate paper profits, but you cannot massage the Cash Flow Statement. The cash either went out the door to buy machines, or it stayed in the bank. Hartalega's RM 1.1 Billion cash pile is real, and it is growing.
My Strategy: Survive the Bleed, Ride the Consolidation
I am holding my shares. Not because I believe in a "glove boom," but because I believe in the math.
1. Break-Even Analysis: In the current market (ASP US$19–20), Hartalega is still operating 80% above its break-even point. They are not at risk of bankruptcy.
2. The Game of Chicken: The current price war cannot last forever. When Intco runs out of cash and is forced to raise prices, Hartalega will be the last man standing, with the lowest cost structure and the cleanest balance sheet.
3. The Exit: When that consolidation occurs, the market will re-rate Hartalega violently to the upside.
The market is pricing Hartalega as if Intco will win. But the math proves Intco will run out of money before Hartalega runs out of patience.
Disclaimer: This is a personal analysis based on publicly available financial data and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
